Published in Neurobiol Aging on August 08, 2008
Hypothetical model of dynamic biomarkers of the Alzheimer's pathological cascade. Lancet Neurol (2010) 19.42
Serial PIB and MRI in normal, mild cognitive impairment and Alzheimer's disease: implications for sequence of pathological events in Alzheimer's disease. Brain (2009) 7.20
The clinical use of structural MRI in Alzheimer disease. Nat Rev Neurol (2010) 4.59
MRI and CSF biomarkers in normal, MCI, and AD subjects: diagnostic discrimination and cognitive correlations. Neurology (2009) 2.83
Combining MR imaging, positron-emission tomography, and CSF biomarkers in the diagnosis and prognosis of Alzheimer disease. AJNR Am J Neuroradiol (2010) 2.61
Longitudinal change of biomarkers in cognitive decline. Arch Neurol (2011) 2.51
CSF biomarkers in prediction of cerebral and clinical change in mild cognitive impairment and Alzheimer's disease. J Neurosci (2010) 2.18
Brain atrophy in healthy aging is related to CSF levels of Aβ1-42. Cereb Cortex (2010) 1.79
Cerebrospinal fluid biomarkers and rate of cognitive decline in very mild dementia of the Alzheimer type. Arch Neurol (2009) 1.68
Brain tissue volumes in the general population of the elderly: the AGES-Reykjavik study. Neuroimage (2011) 1.28
Reduced sample sizes for atrophy outcomes in Alzheimer's disease trials: baseline adjustment. Neurobiol Aging (2010) 1.21
Biomarkers in translational research of Alzheimer's disease. Neuropharmacology (2010) 1.11
Baseline CSF p-tau levels independently predict progression of hippocampal atrophy in Alzheimer disease. Neurology (2009) 1.10
Sex differences in grey matter atrophy patterns among AD and aMCI patients: results from ADNI. Neuroimage (2011) 1.04
Phosphorylated tau 231, memory decline and medial temporal atrophy in normal elders. Neurobiol Aging (2010) 0.98
Vascular and Alzheimer's disease markers independently predict brain atrophy rate in Alzheimer's Disease Neuroimaging Initiative controls. Neurobiol Aging (2013) 0.95
MRI markers for mild cognitive impairment: comparisons between white matter integrity and gray matter volume measurements. PLoS One (2013) 0.94
Effects of cerebrospinal fluid proteins on brain atrophy rates in cognitively healthy older adults. Neurobiol Aging (2013) 0.94
Cerebrospinal fluid biomarkers in mild cognitive impairment and dementia. J Alzheimers Dis (2010) 0.93
White matter hyperintensities and amyloid are independently associated with entorhinal cortex volume among individuals with mild cognitive impairment. Alzheimers Dement (2013) 0.92
Alzheimer's disease markers, hypertension, and gray matter damage in normal elderly. Neurobiol Aging (2011) 0.90
Cerebrospinal fluid biomarkers of Alzheimer's disease in healthy elderly. Front Biosci (Landmark Ed) (2013) 0.89
Role of structural MRI in Alzheimer's disease. Alzheimers Res Ther (2010) 0.88
Diagnostic accuracy of markers for prodromal Alzheimer's disease in independent clinical series. Alzheimers Dement (2013) 0.86
Impact of apolipoprotein E4-cerebrospinal fluid β-amyloid interaction on hippocampal volume loss over 1 year in mild cognitive impairment. Alzheimers Dement (2011) 0.85
Biomarkers predicting Alzheimer's disease in cognitively normal aging. J Clin Neurol (2011) 0.84
Characterising the grey matter correlates of leukoaraiosis in cerebral small vessel disease. Neuroimage Clin (2015) 0.83
Calibrating longitudinal cognition in Alzheimer's disease across diverse test batteries and datasets. Neuroepidemiology (2014) 0.82
Measuring brain atrophy with a generalized formulation of the boundary shift integral. Neurobiol Aging (2014) 0.82
The mediational effects of FDG hypometabolism on the association between cerebrospinal fluid biomarkers and neurocognitive function. Neuroimage (2014) 0.81
Cerebrospinal fluid proteins predict longitudinal hippocampal degeneration in early-stage dementia of the Alzheimer type. Alzheimer Dis Assoc Disord (2012) 0.81
Discriminant analysis of intermediate brain atrophy rates in longitudinal diagnosis of Alzheimer's disease. Diagn Pathol (2011) 0.78
Does CSF p-tau181 help to discriminate Alzheimer's disease from other dementias and mild cognitive impairment? A meta-analysis of the literature. J Neural Transm (Vienna) (2014) 0.77
Genetic variation modifies risk for neurodegeneration based on biomarker status. Front Aging Neurosci (2014) 0.77
Analysis of spatio-temporal brain imaging patterns by Hidden Markov Models and serial MRI images. Hum Brain Mapp (2014) 0.76
T1rho MRI and CSF biomarkers in diagnosis of Alzheimer's disease. Neuroimage Clin (2015) 0.75
High tau levels in cerebrospinal fluid predict nursing home placement and rapid progression in Alzheimer's disease. Alzheimers Res Ther (2016) 0.75
Prediction of Mild Cognitive Impairment Conversion Using a Combination of Independent Component Analysis and the Cox Model. Front Hum Neurosci (2017) 0.75
Clinical Application of Automatic Segmentation of Medial Temporal Lobe Subregions in Prodromal and Dementia-Level Alzheimer's Disease. J Alzheimers Dis (2016) 0.75
A Systematic Review of Longitudinal Studies Which Measure Alzheimer's Disease Biomarkers. J Alzheimers Dis (2017) 0.75
The diagnosis of dementia due to Alzheimer's disease: recommendations from the National Institute on Aging-Alzheimer's Association workgroups on diagnostic guidelines for Alzheimer's disease. Alzheimers Dement (2011) 24.26
Research criteria for the diagnosis of Alzheimer's disease: revising the NINCDS-ADRDA criteria. Lancet Neurol (2007) 18.62
Oral fingolimod or intramuscular interferon for relapsing multiple sclerosis. N Engl J Med (2010) 13.82
Mild cognitive impairment. Lancet (2006) 10.21
Revising the definition of Alzheimer's disease: a new lexicon. Lancet Neurol (2010) 8.74
CSF biomarkers and incipient Alzheimer disease in patients with mild cognitive impairment. JAMA (2009) 7.29
Risk of dementia in diabetes mellitus: a systematic review. Lancet Neurol (2006) 6.97
Neuroimaging standards for research into small vessel disease and its contribution to ageing and neurodegeneration. Lancet Neurol (2013) 6.18
Evaluation of patients treated with natalizumab for progressive multifocal leukoencephalopathy. N Engl J Med (2006) 5.20
Further Implications of Off-Label Use of Acetazolamide in the Management of Moyamoya Disease in Japan: Response. Radiology (2017) 4.99
The clinical use of structural MRI in Alzheimer disease. Nat Rev Neurol (2010) 4.59
Altered resting state networks in mild cognitive impairment and mild Alzheimer's disease: an fMRI study. Hum Brain Mapp (2005) 4.11
PML in a patient treated with dimethyl fumarate from a compounding pharmacy. N Engl J Med (2013) 4.02
Genome-wide association analysis of susceptibility and clinical phenotype in multiple sclerosis. Hum Mol Genet (2008) 3.93
Ocrelizumab in relapsing-remitting multiple sclerosis: a phase 2, randomised, placebo-controlled, multicentre trial. Lancet (2011) 3.76
Prevalence and prognostic value of CSF markers of Alzheimer's disease pathology in patients with subjective cognitive impairment or mild cognitive impairment in the DESCRIPA study: a prospective cohort study. Lancet Neurol (2009) 3.65
MRI criteria for multiple sclerosis in patients presenting with clinically isolated syndromes: a multicentre retrospective study. Lancet Neurol (2007) 3.47
Long-term effect of early treatment with interferon beta-1b after a first clinical event suggestive of multiple sclerosis: 5-year active treatment extension of the phase 3 BENEFIT trial. Lancet Neurol (2009) 3.42
Effect of rivastigmine on delay to diagnosis of Alzheimer's disease from mild cognitive impairment: the InDDEx study. Lancet Neurol (2007) 3.22
Comparison of fingolimod with interferon beta-1a in relapsing-remitting multiple sclerosis: a randomised extension of the TRANSFORMS study. Lancet Neurol (2011) 3.16
Amyloid-related imaging abnormalities in amyloid-modifying therapeutic trials: recommendations from the Alzheimer's Association Research Roundtable Workgroup. Alzheimers Dement (2011) 3.05
Maternal segregation of the Dutch preeclampsia locus at 10q22 with a new member of the winged helix gene family. Nat Genet (2005) 2.88
Mechanism of amyloid removal in patients with Alzheimer disease treated with gantenerumab. Arch Neurol (2011) 2.75
Chronic cerebrospinal venous insufficiency and multiple sclerosis. Ann Neurol (2010) 2.63
Small vessel disease and general cognitive function in nondisabled elderly: the LADIS study. Stroke (2005) 2.59
Progression of white matter hyperintensities and incidence of new lacunes over a 3-year period: the Leukoaraiosis and Disability study. Stroke (2008) 2.57
Cognitive impairment in heart failure: a systematic review of the literature. Eur J Heart Fail (2006) 2.56
Intracortical lesions in multiple sclerosis: improved detection with 3D double inversion-recovery MR imaging. Radiology (2005) 2.47
Heterogeneity of small vessel disease: a systematic review of MRI and histopathology correlations. J Neurol Neurosurg Psychiatry (2010) 2.44
MRI and the diagnosis of multiple sclerosis: expanding the concept of "no better explanation". Lancet Neurol (2006) 2.44
Profile of cognitive impairment in chronic heart failure. J Am Geriatr Soc (2007) 2.43
Midlife blood pressure and the risk of hippocampal atrophy: the Honolulu Asia Aging Study. Hypertension (2004) 2.43
Brain imaging in patients with diabetes: a systematic review. Diabetes Care (2006) 2.39
Amyloid-beta(1-42), total tau, and phosphorylated tau as cerebrospinal fluid biomarkers for the diagnosis of Alzheimer disease. Clin Chem (2009) 2.32
Measurement of atrophy in multiple sclerosis: pathological basis, methodological aspects and clinical relevance. Brain (2002) 2.30
Prediction of conversion from mild cognitive impairment to Alzheimer's disease dementia based upon biomarkers and neuropsychological test performance. Neurobiol Aging (2010) 2.27
Pooled analysis of prognostic impact of urokinase-type plasminogen activator and its inhibitor PAI-1 in 8377 breast cancer patients. J Natl Cancer Inst (2002) 2.25
Frontotemporal dementia in The Netherlands: patient characteristics and prevalence estimates from a population-based study. Brain (2003) 2.20
Magnetic resonance imaging pattern recognition in hypomyelinating disorders. Brain (2010) 2.19
Early-onset versus late-onset Alzheimer's disease: the case of the missing APOE ɛ4 allele. Lancet Neurol (2010) 2.18
Loss of 'small-world' networks in Alzheimer's disease: graph analysis of FMRI resting-state functional connectivity. PLoS One (2010) 2.12
Clinically isolated syndromes suggestive of multiple sclerosis, part I: natural history, pathogenesis, diagnosis, and prognosis. Lancet Neurol (2005) 2.10
MRI in multiple sclerosis: current status and future prospects. Lancet Neurol (2008) 2.08
Cortical lesions in multiple sclerosis: combined postmortem MR imaging and histopathology. AJNR Am J Neuroradiol (2005) 2.07
Grey matter volume in a large cohort of MS patients: relation to MRI parameters and disability. Mult Scler (2011) 2.07
Lack of association between antimyelin antibodies and progression to multiple sclerosis. N Engl J Med (2007) 2.06
Medial temporal lobe atrophy on MRI predicts dementia in patients with mild cognitive impairment. Neurology (2004) 2.00
Designing drug trials for Alzheimer's disease: what we have learned from the release of the phase III antibody trials: a report from the EU/US/CTAD Task Force. Alzheimers Dement (2013) 1.98
Grey matter pathology in multiple sclerosis. Lancet Neurol (2008) 1.97
Advances in the early detection of Alzheimer's disease. Nat Med (2004) 1.97
Interferon beta-1a for brain tissue loss in patients at presentation with syndromes suggestive of multiple sclerosis: a randomised, double-blind, placebo-controlled trial. Lancet (2004) 1.93
Impact of age-related cerebral white matter changes on the transition to disability -- the LADIS study: rationale, design and methodology. Neuroepidemiology (2005) 1.92
Impact of white matter hyperintensities scoring method on correlations with clinical data: the LADIS study. Stroke (2006) 1.88
The Alzheimer's Association external quality control program for cerebrospinal fluid biomarkers. Alzheimers Dement (2011) 1.87
The effect of amyloid associated proteins on the expression of genes involved in amyloid-β clearance by adult human astrocytes. Exp Neurol (2011) 1.85
Intravenous immunoglobulin for treatment of mild-to-moderate Alzheimer's disease: a phase 2, randomised, double-blind, placebo-controlled, dose-finding trial. Lancet Neurol (2013) 1.84
Brain microbleeds and Alzheimer's disease: innocent observation or key player? Brain (2011) 1.82
Inflammatory markers in AD and MCI patients with different biomarker profiles. Neurobiol Aging (2008) 1.82
Precuneus atrophy in early-onset Alzheimer's disease: a morphometric structural MRI study. Neuroradiology (2007) 1.80
Comparison of two dosing frequencies of subcutaneous interferon beta-1a in patients with a first clinical demyelinating event suggestive of multiple sclerosis (REFLEX): a phase 3 randomised controlled trial. Lancet Neurol (2011) 1.79
Intrathecal chemokine synthesis in mild cognitive impairment and Alzheimer disease. Arch Neurol (2006) 1.79
Shining a light on posterior cortical atrophy. Alzheimers Dement (2012) 1.77
Relationship of cerebrospinal fluid markers to 11C-PiB and 18F-FDDNP binding. J Nucl Med (2009) 1.77
Imaging markers for Alzheimer disease: which vs how. Neurology (2013) 1.76
Unusual variants of Alexander's disease. Ann Neurol (2005) 1.76
Deficits of memory, executive functioning and attention following infarction in the thalamus; a study of 22 cases with localised lesions. Neuropsychologia (2003) 1.76
On the etiology of incident brain lacunes: longitudinal observations from the LADIS study. Stroke (2008) 1.75
Association between pathological and MRI findings in multiple sclerosis. Lancet Neurol (2012) 1.70
Effects of processing and storage conditions on amyloid beta (1-42) and tau concentrations in cerebrospinal fluid: implications for use in clinical practice. Clin Chem (2004) 1.68
Improved detection of active multiple sclerosis lesions: 3D subtraction imaging. Radiology (2010) 1.68